Stock Updates

Is this Large Market Cap Stock target price reasonable for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

The company in question is, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) currently with a stock price of 24.37 (-3.26% today). The market cap for ACADIA Pharmaceuticals Inc. is 3075.95, and is in the sector Healthcare, and Biotechnology industry. The target price for ACADIA Pharmaceuticals Inc. is 44.78. Currently ACADIA Pharmaceuticals Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for ACADIA Pharmaceuticals Inc. is 2086.13 and so far today it is 1914876.

Performance in the last year for ACADIA Pharmaceuticals Inc. has been -21.48%. For EPS growth, ACADIA Pharmaceuticals Inc. has seen a growth of -71.80%, and is looking to grow in the next year to 30.40%. More long term stats show that EPS growth has been -43.90% over the last five years and could be 9.50% for the next five years. ACADIA Pharmaceuticals Inc. has seen sales growth quarter over quarter at 9600.00%, with EPS growth quarter over quarter at -60.40%. The 20-day simple moving average is -24.48%, with the 200-day simple moving average coming to -18.27%.

Since the IPO date for ACADIA Pharmaceuticals Inc. on the 5/27/2004, ACADIA Pharmaceuticals Inc. has seen performance year to date to be -29.34%. With ACADIA Pharmaceuticals Inc. trading at 24.37, the dividend yield is *TBA, and the EPS is -1.92.

So could ACADIA Pharmaceuticals Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 15379.75 and the P/B is at 6.98. The P/cash is 7.46, with P/free cash flow at *TBA.

ACADIA Pharmaceuticals Inc. ability to deal with debt shows that the current ratio is 14.6, and the quick ratio is 14.5. This is with long term debt/equity at 0, and total debt/equity at 0.

In terms of margins, ACADIA Pharmaceuticals Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for ACADIA Pharmaceuticals Inc. is *TBA. Return on assets come to -60.00% with return on investment coming to *TBA.

Insider ownership for ACADIA Pharmaceuticals Inc., is at 0.20% and institutional ownership comes to 96.50%. Outstanding shares are at 122.11. While shares float is 119.49. The float short is currently 15.23%, and short ratio is 8.72.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Tony Dabbs

Leave a Comment